ASRT: Assertio Holdings, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 96.29
Enterprise Value ($M) 90.28
Book Value ($M) 132.15
Book Value / Share 1.39
Price / Book 0.73
NCAV ($M) 30.56
NCAV / Share 0.32
Price / NCAV 3.15

Profitability (mra)
Return on Invested Capital (ROIC) -2.00
Return on Assets (ROA) -0.91
Return on Equity (ROE) -1.79

Liquidity (mrq)
Quick Ratio 1.51
Current Ratio 1.93

Balance Sheet (mrq) ($M)
Current Assets 177.85
Assets 279.44
Liabilities 147.29
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
7 days ago 13G/A Vanguard Group Inc 4.68 -8.37
07-08 13G/A BlackRock Inc. 1.50 -78.92
02-14 13G/A Continental General Insurance Co 0.00 -100.00
02-14 13G/A Armistice Capital, Llc 6.13
02-14 13G Nantahala Capital Management, LLC 8.00

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-03-11 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-08 1,144,238 4,395,167 26.03
2024-11-07 99,456 317,363 31.34
2024-11-06 172,241 630,049 27.34
2024-11-05 210,359 532,789 39.48

(click for more detail)

Similar Companies
APVO – Aptevo Therapeutics Inc. ARTL – Artelo Biosciences, Inc.
ASNS – Actelis Networks, Inc. ATNF – 180 Life Sciences Corp.
ATOS – Atossa Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io